Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133425) titled 'A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer' on Aug. 19.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Non-Small Cell Lung Cancer
ICI-refractory
Intervention:
Drug: SAR445877
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 5, 2026
Target Sample Size: 29
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/ct2/s...